Abstract:Isocitrate dehydrogenase (IDH) inhibitors are transforming the treatment of patients with non-enhancing grade 2 IDH-mutant gliomas. Uncertainty remains on the utility of IDH-inhibitors in high-grade IDH-mutant glioma patients that had prior therapies and have progressive disease. From October 2020 to December 2023, we identified high-grade IDH1-mutant patients treated with off-label ivosidenib, a mutant IDH1 inhibitor. We report their clinical and imaging characteristics. In our cohort (n=18), the patient age range was 29-68 years with male predominance (n=11). Diagnoses included astrocytoma grades 3 (n=9) or 4 (n=2), and oligodendroglioma grade 3 (n=7). The median number of progressions prior to ivosidenib initiation was 2 (range 1-7). Fifteen patients had prior surgical resection, three had biopsy. Prior treatment exposures included radiation therapy (n=15), temozolomide (n=18), lomustine (n=5), bevacizumab (n=3), etoposide (n=1), optune (n=1) and a clinical trial (n=1). Mean time from diagnosis to ivosidenib treatment was 9.6 years (95% CI, 6.7 to 16.4 years). Karnofsky performance-status score upon initiation was 80 (n=6) or 90 (n=12). Thirteen patients had >1 cm enhancing disease, five had non-enhancing disease. Ivosidenib was initiated due to enhancing disease progression (n=11), non-enhancing disease progression (n=4), a combination of both (n=2) or temozolomide intolerance (n=1). Best radiographic responses per RANO criteria were partial response (n=2), minor response (n=3), stable disease (n=7), and progressive disease (n=6). Nine patients continue ivosidenib without disease progression, with a median treatment duration of 27.5 months (95% CI, 18.0 to 33.0 months). All had FLAIR stabilization/improvement and 45% (n=4) had improved enhancing disease. Nine patients discontinued ivosidenib due to progression, with a median treatment duration of 7 months (95% CI, 3 to 9 months). These data suggest that treatment with an IDH inhibitor can provide disease control for some high-grade IDH-mutant glioma patients who had prior therapies and progressive disease. Future studies are needed to investigate this patients population.

Advances in the treatment of IDH-mutant gliomas

The Role of Mutant IDH Inhibitors in the Treatment of Glioma

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors

Treatment of IDH-mutant glioma in the INDIGO era

Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside

Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma

IDH inhibition in gliomas: from preclinical models to clinical trials

Therapies for IDH-Mutant Gliomas

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment

Targeting IDH-Mutant Glioma

Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises-a narrative review

To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma

Multidisciplinary Management of Isocitrate Dehydrogenase–Mutated Gliomas in a Contemporary Molecularly Defined Era

Treatment Options for IDH-Mutant Malignant Gliomas

IDH mutation in glioma: molecular mechanisms and potential therapeutic targets

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical Implications

Innv-37. Real-World Outcomes Among High Grade Idh1-Mutant Glioma Patients Treated With An Idh Inhibitor

Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma

Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.

Exth-08. Ivosidenib Therapy For Idh-Mutant Who Grade 4 Astrocytoma

Advances in Immune Microenvironment and Immunotherapy of Isocitrate Dehydrogenase Mutated Glioma